Guillen Nieto

Gerardo E. Guillen Nieto, Ciudad De La Habana CU

Patent application number	Description	Published
20080312139	Use of Pharmaceutical Composition Containing Epidermal Growth Factor (EGF) for Diabetic foot Amputation Prevention - The invention relates to the use of Epidermal Growth Factor (EGF) in a preferably-Injectable pharmaceutical composition which is administered by means of infiltration into and around chronic cutaneous ischaemic lesions in order to prevent diabetic foot amputation. Said composition can be administered to recently-created surgical surfaces damaged by the effect of acute reperfusion with oxygenated blood following prolonged ischaemia, thereby preventing further surgical procedures and favouring the preservation of the extremity. The aforementioned composition can be used to improve (i) the cell microenvironment, thereby increasing the reparative and defensive capacity and viability of the is tissues and (ii) the cicatrisation of cutaneous ischaemic lesions, thereby stimulating cell proliferation. The invention is suitable for use in human, veterinary and experimental medicine, specifically in vascular angiology and surgery, dermatology, burn treatment and reconstructive surgery and geriatric medicine. Said composition can be used for recalcitrant ulcers which are associated with lesions in the macro and/or microvasculature, patients with inadequate lymphatic and/or venous return and ulcers or other lesions which are difficult to cicatrise and/or heal.	12-18-2008

Gerardo Enrique Guillen Nieto, C. Habana CU

Patent application number	Description	Published
20090104223	Method for Obtaining Antigenic Aggregates and the Use Thereof in Formulations - The invention relates to a method for obtaining aggregated antigenic structures that are capable of enhancing an immune response to aggregate antigens administered systemically and/or mucosally generating powerful immune response and to the chemical structures resulting from the application of said method, to the formulations obtained from such structures and their use. The method describes the obtention of novel aggregate antigenic structures by using aggregating, delipidating or oxidating agents or compounds enabling the release of lipids from the particles and their heterogeneous aggregation, wherein aggregates with particle sizes of between 30 and 500 nm are subsequently selected by means of a molecular exclusion process. The aggregation state can also be provoket inside the yeast by changing incubation conditions. The resulting structures can be used conveniently adjuvated or in a formulation in which several antigens can be introduced, wherein synergism between said components is found with respect to the immunogenicity of the response obtained. The preparation may also contain stabilizers and preservatives. The resulting antigenic structures can be used in the pharmaceutical industry as preventive or therapeutic vaccine formulation both for human and veterinary use and as part of diagnostic system.	04-23-2009

Gerardo Enrique Guillen Nieto, Ciudad Habana CU

Patent application number	Description	Published
20110250196	PHARMACEUTICAL COMPOSITION USING GONADOTROPIN - RELEASING HORMONE (GNRH) COMBINED VARIANTS AS IMMUNOGEN - A pharmaceutical composition using natural gonadotropin-releasing hormone (GnRH), and/or some of its mimetic peptides, indistinctly bound by its amino or carboxyl extremes to a carrier molecule; in one case by its carboxyl extreme and in the other case by the amino terminal extreme, thus eliciting a faster and more potent immunological response against the endogenous GnRH hormone. This finally leads to the ablation of the GnRH and consequently of the rest of the involved hormones in the stream GnRH/LH-FSH/Testosterone-(estrogens). An advantage of this formulation consists on facilitating the exposition to the immune system of a greater number of epitopes of the GnRH or its mimetics, minimizing thus the steric hindrance produced by the carriers. This invention has a direct application in the castration of pets and animals of economic interest, in the control of human fertility as well as in the treatment of hormone-sensitive tumors, such as that of the prostate, the breast, ovary, the endometry, testicles, hypophysis, salivary glands and other kinds of human tumors.	10-13-2011
20150190491	Pharmaceutical Composition Using Gonadotropin-Releasing Hormone (GNRH) Combined Variants as Immunogen - A pharmaceutical composition using natural gonadotropin—releasing hormone (GnRH), and/or some of its mimetic peptides, indistinctly bound by its amino or carboxyl extremes to a carrier molecule; in one case by its carboxyl extreme and in the other case by the amino terminal extreme, thus eliciting a faster and more potent immunological response against the endogenous GnRH hormone. This finally leads to the ablation of the GnRH and consequently of the rest of the involved hormones in the stream GnRH/LH-FSH/Testosterone-(estrogens). An advantage of this formulation consists on facilitating the exposition to the immune system of a greater number of epitopes of the GnRH or its mimetics, minimizing thus the steric hindrance produced by the carriers. This invention has a direct application in the castration of pets and animals of economic interest, in the control of human fertility as well as in the treatment of hormone-sensitive tumors, such as that of the prostate, the breast, ovary, the endometry, testicles, hypophysis, salivary glands and other kinds of human tumors.	07-09-2015

Gerardo Enrique Guillén Nieto, La Habana CU

Patent application number	Description	Published
20120308615	FORMULATION OF HEPATITIS B VIRUS ANTIGENS FOR CELLULAR STIMULATION FOLLOWED BY THERAPEUTIC IMMUNIZATION - The present invention is related with the field of the therapeutic immunization, specifically with the employment of a new formulation of antigens of the Hepatitis B Virus (HBV) for the cellular stimulation. The formulation is formed by the surface antigens (HBsAg) precipitated in suspension and the nucleocapsid (HBcAg) of the HBV. The formulation contains these antigens like suspended particles of sizes less than 500 nm and higher than 500 nm, in a mixture where the proportion among the particles of the mentioned sizes is among 50%-50% and 80%-20%, respectively. The selection of a range of sizes of particles allows that the levels of stimulation of several cellular types are maximized. Additionally, a cellular stimulation method is described with this formulation, and the later passive immunization of patients with chronic Hepatitis B, based on the maximum stimulation in vivo or in vitro using heterologous or autologous cells (dendritic cells, B cells and macrophages). The cells stimulated with this formulation are transferred to patients chronically infected with the HBV.	12-06-2012

Gerardo Enrique Guillén Nieto, La Habana CU

Patent application number	Description	Published
20120308615	FORMULATION OF HEPATITIS B VIRUS ANTIGENS FOR CELLULAR STIMULATION FOLLOWED BY THERAPEUTIC IMMUNIZATION - The present invention is related with the field of the therapeutic immunization, specifically with the employment of a new formulation of antigens of the Hepatitis B Virus (HBV) for the cellular stimulation. The formulation is formed by the surface antigens (HBsAg) precipitated in suspension and the nucleocapsid (HBcAg) of the HBV. The formulation contains these antigens like suspended particles of sizes less than 500 nm and higher than 500 nm, in a mixture where the proportion among the particles of the mentioned sizes is among 50%-50% and 80%-20%, respectively. The selection of a range of sizes of particles allows that the levels of stimulation of several cellular types are maximized. Additionally, a cellular stimulation method is described with this formulation, and the later passive immunization of patients with chronic Hepatitis B, based on the maximum stimulation in vivo or in vitro using heterologous or autologous cells (dendritic cells, B cells and macrophages). The cells stimulated with this formulation are transferred to patients chronically infected with the HBV.	12-06-2012
20140356319	Compounds and pharmaceutical combinations for the treatment of neurodegenerative and ischemic brain diseases - The present invention describes peptides comprising phycocyanobilin (PCB), as well as the medical use of said peptides and that of PCB, due to the neuroprotector and/or neuroregenerative effects identified for them. Furthermore, pharmaceutical combinations of said peptides and of PCB with proteins or other peptides with synergic effect justify their use for ischemic or neurodegenerative CNS disease treatment.	12-04-2014

Gerardo Enrique Guillén Nieto, Plaza De La Revolución, La Habana CU

Patent application number	Description	Published
20150328304	DENGUE VIRUS VACCINE COMPOSITION - Vaccine compositions that comprise at least one antigen based on the dengue virus (DV) capsid protein and the oligonucleotide identified as SEQ ID NO 1. The vaccine composition that comprises a fusion protein formed by the DV2 capsid and domain III of the envelope protein of the same serotype, together with the oligonucleotide identified as SEQ ID NO 1, gives rise to higher levels of cellular immune response and protection in mice as compared with that produced by formulations of the same antigen together with oligonucleotides with potential adjuvant capacity which were reported previously. The efficacy of the compositions that comprise the SEQ ID NO 1 oligonucleotide has been demonstrated in non-human primates. These compositions may be monovalent, bivalent or tetravalent and are combined in different immunization regimes with a view to inducing a functional immune response to the four viral serotypes.	11-19-2015